Trial Profile
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Capecitabine; Cisplatin; Docetaxel; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms KEYNOTE-585; MK-3475-585/KEYNOTE-585
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 20 Jan 2024 Interim results (at data cut off: 09 Feb 2023; n=203) assessing safety and efficacy analyses of the FLOT cohort, presented at the 2024 Gastrointestinal Cancers Symposium.
- 19 Dec 2023 Results assessing the antitumor activity of neoadjuvant and adjuvant pembrolizumab plus chemotherapy in patients with locally advanced resectable gastric or gastrooesophageal adenocarcinoma, published in the Lancet Oncology
- 24 Oct 2023 Results of pre-specified third interim analysis were presented at the 48th European Society for Medical Oncology Congress.